Trichostatin A (TSA)

Name: Trichostatin A (TSA)
Brand: Selleck Chemicals
SKU: S1045
Rating: 5 (160 reviews)

For research use only.

Catalog No.S1045

160 publications

CAS No. 58880-19-6

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Selleck's Trichostatin A (TSA) has been cited by 160 publications

Cell, 2019, 178(5):1115-1131

PubMed: 31442404 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell, 2017, 171(4):824-835.e18

PubMed: 29056338 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Cancer Cell, 2014, 26(4):534-48

PubMed: 25314079 ( click the link to review the publication )

Neoplasia, 2021, 23(1):129-139

PubMed: 33316537 ( click the link to review the publication )

Autophagy, 2020, 10.1080/15548627.2019.1709762

PubMed: 31986961 ( click the link to review the publication )

Autophagy, 2020, 15:1-13

PubMed: 32264736 ( click the link to review the publication )

Theranostics, 2020, 10(21):9644-9662

PubMed: 32863951 ( click the link to review the publication )

Theranostics, 2020, 10(15):6790-6805

PubMed: 32550904 ( click the link to review the publication )

Cell Rep, 2020, 33(11):108507

PubMed: 33326790 ( click the link to review the publication )

mBio, 2020, 11(5)e02343-20

PubMed: 33024042 ( click the link to review the publication )

Free Radic Biol Med, 2020, 10.1016/j.freeradbiomed.2020.01.016

PubMed: 31972340 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):765

PubMed: 32943605 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 13;5(1):53

PubMed: 32398667 ( click the link to review the publication )

Cells, 2020, 21;9(5):E1280

PubMed: 32455774 ( click the link to review the publication )

Front Immunol, 2020, 3;11:36

PubMed: 32117228 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.0417.2020

PubMed: 33277442 ( click the link to review the publication )

Mol Neurobiol, 2020, 10.1007/s12035-019-01812-5

PubMed: 31919777 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(2):523-535

PubMed: 32195024 ( click the link to review the publication )

Oncogenesis, 2020, 13;9(5):48

PubMed: 32404892 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Immunol Cell Biol, 2020, 98(4):318-331

PubMed: 31950542 ( click the link to review the publication )
Front Chem, 2020, 23;8:184

PubMed: 32266211 ( click the link to review the publication )

J Immunol Res, 2020, 2020:7263602

PubMed: 33062724 ( click the link to review the publication )

BMC Microbiol, 2020, 20(1):28

PubMed: 32028887 ( click the link to review the publication )

Arch Insect Biochem Physiol, 2020, 103(4):e21649

PubMed: 31777104 ( click the link to review the publication )

Cell Rep, 2020, 30(7):2195-2208

PubMed: 32075759 ( click the link to review the publication )

Theranostics, 2020, 10(17):7747-7757

PubMed: 32685017 ( click the link to review the publication )

Theranostics, 2020, 10(5):2188-2200

PubMed: 32104503 ( click the link to review the publication )

Mol Cell, 2019, 73(4):788-802

PubMed: 30704899 ( click the link to review the publication )

Mol Cell, 2019, 74(6):1250-1263

PubMed: 31054974 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5792

PubMed: 31857589 ( click the link to review the publication )

Nat Commun, 2019, 10(1):4353

PubMed: 31554795 ( click the link to review the publication )

Nat Commun, 2019, 10(1):5800

PubMed: 31863007 ( click the link to review the publication )

Nucleic Acids Res, 2019, 19;47(16):8502-8520

PubMed: 31616951 ( click the link to review the publication )

Autophagy, 2019, 1-13

PubMed: 30957628 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1707488

PubMed: 31878840 ( click the link to review the publication )

PLoS Biol, 2019, 17(10):e3000461

PubMed: 31600191 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

J Cell Biol, 2019, 218(1):267-284

PubMed: 30538141 ( click the link to review the publication )

J Cell Biol, 2019, 218(12):4017-4029

PubMed: 31645458 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32425

PubMed: 31111958 ( click the link to review the publication )

Mol Ther, 2019, 27(5):1039-1050

PubMed: 30852137 ( click the link to review the publication )

EBioMedicine, 2019, 43:238-252

PubMed: 31047858 ( click the link to review the publication )

J Bone Miner Res, 2019, 10.1002/jbmr.3716

PubMed: 31112333 ( click the link to review the publication )
J Exp Clin Cancer Res, 2019, 38(1):428

PubMed: 31665064 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):84

PubMed: 30777099 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):463

PubMed: 31718704 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz093

PubMed: 31560394 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Neurobiol, 2019, 10.1007/s12035-019-1565-7

PubMed: 30963442 ( click the link to review the publication )

J Mol Med (Berl), 2019, 97(4):541-552

PubMed: 30806715 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3442-3452

PubMed: 31432592 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

J Virol, 2019, 93(4)e01896-18

PubMed: 30518648 ( click the link to review the publication )

Front Cell Neurosci, 2019, 13:468

PubMed: 31708743 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Sci Rep, 2019, 9(1):4360

PubMed: 30867438 ( click the link to review the publication )

PLoS Comput Biol, 2019, 15(2):e1006826

PubMed: 30785874 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

Life Sci, 2019, 223:1-8

PubMed: 30862568 ( click the link to review the publication )

J Cell Biochem, 2019, 10.1002/jcb.29470

PubMed: 31692090 ( click the link to review the publication )

Cell Adh Migr, 2019, 13(1):285-292

PubMed: 31271097 ( click the link to review the publication )

Alcohol Clin Exp Res, 2019, 43(5):822-832

PubMed: 30860602 ( click the link to review the publication )

Oncol Rep, 2019, 41(6):3209-3218

PubMed: 31002353 ( click the link to review the publication )

Int J Mol Med, 2019, 44(5):1789-1800

PubMed: 31545402 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):285-293

PubMed: 30387821 ( click the link to review the publication )

Tuberculosis (Edinb), 2019, 118:101861

PubMed: 31526947 ( click the link to review the publication )
ACS Omega, 2019, 4(22):19895-19904

PubMed: 31788622 ( click the link to review the publication )

Reprod Fertil Dev, 2019, 31(3):473-481

PubMed: 30301509 ( click the link to review the publication )

Res Vet Sci, 2019, 126:207-212

PubMed: 31610471 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )

Sci Adv, 2019, 5(3):eaav1118

PubMed: 30944854 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

J Clin Invest, 2018, 128(9):4098-4114

PubMed: 30124467 ( click the link to review the publication )

Cell Rep, 2018, 24(7):1722-1729

PubMed: 30110629 ( click the link to review the publication )

Mol Ther, 2018, 26(7):1828-1839

PubMed: 29730197 ( click the link to review the publication )

Oncogene, 2018, 37(50):6414-6424

PubMed: 30068939 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Mol Oncol, 2018, 12(5):724-755

PubMed: 29577611 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

J Proteome Res, 2018, 17(4):1436-1451

PubMed: 29564889 ( click the link to review the publication )

Plant Cell Rep, 2018, 37(1):115-123

PubMed: 28939922 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Int Immunopharmacol, 2018, 65:303-311

PubMed: 30342347 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1892-1900

PubMed: 29393444 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 503(2):420-427

PubMed: 29649477 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Med Sci Monit, 2018, 24:461-472

PubMed: 29363667 ( click the link to review the publication )

Curr Protoc Pharmacol, 2018, 81(1):e41

PubMed: 29927058 ( click the link to review the publication )

Sci Rep, 2018, 8(1):13072

PubMed: 30166563 ( click the link to review the publication )

Cell Res, 2017, 27(7):898-915

PubMed: 28497810 ( click the link to review the publication )
Mol Cell, 2017, 67(4):566-578

PubMed: 28803781 ( click the link to review the publication )

Cell Mol Immunol, 2017, 14(4):371-379

PubMed: 26388239 ( click the link to review the publication )

Oncogene, 2017, 36(12):1707-1720

PubMed: 27694895 ( click the link to review the publication )

Chemistry, 2017, 23(13):3107-3116

PubMed: 27922200 ( click the link to review the publication )

Cancer Epidemiol Biomarkers Prev, 2017, 26(9):1411-1419

PubMed: 28619831 ( click the link to review the publication )

Eur J Med Chem, 2017, 127:531-553

PubMed: 28109947 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

J Diabetes Res, 2017, 2017:8208065

PubMed: 28191472 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):51-60

PubMed: 28110187 ( click the link to review the publication )

PLoS One, 2017, 12(10):e0186620

PubMed: 29045501 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 485(2):454-460

PubMed: 28192116 ( click the link to review the publication )

Oncotarget, 2017, 8(11):17995-18009

PubMed: 28152508 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )

Bioorg Med Chem, 2017, 25(7):2105-2132

PubMed: 28259528 ( click the link to review the publication )

Nat Commun, 2016, 7:10690

PubMed: 26891683 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(8):1978-88

PubMed: 26634271 ( click the link to review the publication )

Thorax, 2016, 633-45

PubMed: 27071418 ( click the link to review the publication )

EMBO Rep, 2016, 17(7):999-1012

PubMed: 27154402 ( click the link to review the publication )

J Med Chem, 2016, 59(4):1613-33

PubMed: 26681404 ( click the link to review the publication )

PLoS Pathog, 2016, 12(10):e1005950

PubMed: 27764245 ( click the link to review the publication )

Free Radic Biol Med, 2016, 99:167-178

PubMed: 27498117 ( click the link to review the publication )
Oxid Med Cell Longev, 2016, 2016:4085727

PubMed: 27746856 ( click the link to review the publication )

FEBS J, 2016, 283(20):3739-3754

PubMed: 27573079 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

Mol Cell Biol, 2016, 36(22):2838-2854

PubMed: 27573019 ( click the link to review the publication )

Int J Oncol, 2016, 48(6):2591-607

PubMed: 27082124 ( click the link to review the publication )

BMC Cancer, 2016, 16(1):886

PubMed: 27842508 ( click the link to review the publication )

Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Oncotarget, 2016, 8(60):100975-100988

PubMed: 29254139 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

Tumour Biol, 2016, 37(6):8293-304

PubMed: 26729194 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10269-78

PubMed: 26831669 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Am J Transplant, 2015, 10.1111/ajt.13106

PubMed: 25708614 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1586

PubMed: 25569103 ( click the link to review the publication )

J Antimicrob Chemother, 2015, 10.1093/jac/dku549

PubMed: 25558076 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(2):189-202

PubMed: 25303559 ( click the link to review the publication )

Mol Nutr Food Res, 2015, 59(2):189-202

PubMed: ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

Chem Biol Interact, 2015, 242:227-34

PubMed: 26482938 ( click the link to review the publication )

PLoS One, 2015, 10(3):e0120587

PubMed: 25807249 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )
EMBO J, 2014, 34(1):115-29

PubMed: 25398909 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2014, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2014, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2014, 274(1):7-16

PubMed: 24200994 ( click the link to review the publication )

Life Sci, 2014, 99(1-2):31-6

PubMed: 24486299 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 445(2):320-6

PubMed: 24530917 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):574-80

PubMed: 24607957 ( click the link to review the publication )

Sci Rep, 2014, 4:4663

PubMed: 24722541 ( click the link to review the publication )

Science, 2014, 344(6183):1252304

PubMed: 24727982 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Plant J, 2013, 74(5):815-28

PubMed: 23464703 ( click the link to review the publication )

Cytokine, 2013, 65(2):121-5

PubMed: 24373940 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Epigenetics, 2012, 7(10):1161-72

PubMed: 22965008 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Targets

HDAC ^[1]
(Cell-free assay)

~1.8 nM

In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. ^[1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. ^[2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HEK 293	Mmi1SpVv[3Srb36gRZN{[Xl?	MYGwMlfPxE1?	NIPnfnUzPGh?	MXvleIhidm:u	NX;hflZ[\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W\|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?=	MoHmNlU4QDdyN{m=
TE13	NFnKPGlHfW6ldHnvckBCe3OjeR?=	NX3QOYpZOC5\|zszN	NXnURpplOjSq		MXr1dE1z\We3bHH0[ZMhWkGVU1[1RUBt\X[nbB?=	MUOyOVU4QTZ4NR?=
TE13	MV;BdI9xfG:\|aYOgRZN{[Xl?	NIr6UpYxNjQQvF2=	M3S5eFI1cA>?		NEPMO\|JqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w	NGC2eIozPTV5OU[2OS=>
MEFs	NXn0NI17TnWwY4Tpc44hSXO\|YYm=	NY\rVHRmPc7:TR?=	MUGxOog>		NIPNUGpqdmO{ZXHz[ZMhfGinIFXQSWMh[XS2YXPocYVvfCxiVHnyJIRmdGm4ZYL5JIFv\CC2aHWg[YZncWOrZX7jfUBw\iCyZXTld5RidCCob4LtZZRqd25?	NWLDTHBFOjV2OEK2N\|Q>
SW480	NXe0NXk6TnWwY4Tpc44hSXO\|YYm=	MoPYNE4y\|ryP	NVSwPJY2PDiq	NUjZPVlwTE2VTx?=	MonsdoV3\XK\|ZYOgSW1V	NXnTWpFwOjV2M{S5PVc>
PC3	M37OeGZ2dmO2aX;uJGF{e2G7	MVqwMlHPxE1?	M4HD[VQ5cA>?	NXzPeGc3TE2VTx?=	Ml7SdoV3\XK\|ZYOgSW1V	M3rYWlI2PDN2OUm3
SW480	NGPCOZZHfW6ldHnvckBCe3OjeR?=	NWHHPXdJOC5zzszN	MXe0PIg>	Ml7JSG1UVw>?	MmC2ZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w	MnXkNlU1OzR7OUe=
PC3	MnL1SpVv[3Srb36gRZN{[Xl?	MWiwMlHPxE1?	M2G0TVQ5cA>?	MV7EUXNQ	MmXRZZR1\W63YYTld{Bqdn[jc3nvckBidmRibXnndoF1cW:w	MUKyOVQ{PDl7Nx?=
SW480	MnXsSpVv[3Srb36gRZN{[Xl?	NWXhfnl6OC5zzszN	MUC0PIg>	NE\SPIpFVVOR	MVvpcoR2[2W\|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz	M2Px[VI2PDN2OUm3
PC3	MXvGeY5kfGmxbjDBd5NigQ>?	M{XPd\|AvOc7:TR?=	MnrFOFhp	NFzoOJZFVVOR	NI[1[ItqdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW\|IIDyc41wfGW{	MXGyOVQ{PDl7Nx?=
A431	NX;FNpJ6SXCxcITvd4l{KEG\|c3H5	NYrmcIc{Oi9zMD:1NE8yODCwTR?=	NXi5c5NqPDiq	M2rrfmROW09?	M1T0VIlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aB?=	M1e3c\|I2OzdzME[5
A431	M3zjWGZ2dmO2aX;uJGF{e2G7	M1y4e\|Uxdk1?	NVL4OpFDOi94L{GyM\|I1cA>?	M1X1e2ROW09?	M4m4VoFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?=	M2fybVI2OzdzME[5
MDA-MB-231	MmnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjzUFQxNTZyMH7N	MkDiNlRp	M{P3UmROW09?	M13TO2lEPTBib3[gNVAxdk1?	MknzNlUyQTJ5MkG=
MCF7	M3S1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUWwMVYxOG6P	MWGyOIg>	MlfNSG1UVw>?	M3;5[GlEPTBib3[gO\|VvVQ>?	M4f0NVI2OTl{N{Kx
SKOV-3	Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXtN\|JUOS1zMN88US=>	MWOyOIg>	M4WyN2ROW09?	MVzJR\|UxKG:oIEWuOu69VQ>?	MYWyOVE3QTR7MR?=
A549	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37JZlEuOTEQvF2=	NEPvbm4zPGh?	MUXEUXNQ	NVTvb21ZUUN3MDDv[kA{NjMQvF2=	M{LyOVI2OTZ7NEmx
SKOV-3	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\2W\|AvOS1zzszN	NWLtSmFLPDiq	M4nBR2ROW09?	NY\CO4tRUUN3MDDv[kAxNjgQvF2=	Mm[yNlUyPjl2OUG=
A549	M2XiNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{\HbVAvOS1zzszN	NUOyeYdDPDiq	M2TVPWROW09?	NGqxc4lKSzVyIH;mJFAvOjkQvF2=	Mn[1NlUyPjl2OUG=
SKOV-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLkdnNQOC5yMT2wMlnPxE1?	NWPL[lJGPzKq	M3fDU2ROW09?	M4fXdWlEPTBib3[gNE4{Os7:TR?=	NXrabo9pOjVzNkm0PVE>
A549	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M176elAvODFvMD65{txO	MWG3Nog>	NEfYVXVFVVOR	MlrZTWM2OCCxZjCwMlA3\|ryP	NGTQPY0zPTF4OUS5NS=>
HeLa	MXfGeY5kfGmxbjDBd5NigQ>?	NUG3UYRUOjVybl2=	NInadVYyPmh?	M{K0XGROW09?	NHTuUnRqdmO{ZXHz[ZMhS1mSMVGxJI1TVkFiZYjwdoV{e2mxbtMg	NVfqOmJbOjVzMU[2PFg>
CNE2	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEixd\|EyODBvNkCwcm0>	MlfUNlQwPDhxN{Lo		MYDpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M3mwclI1QTZ7OUCx
PC3	M3;2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX2xNFAuOTByMH7N	MViyOIg>		NGix[ZhKSzVyIH;mJFMxOG6P	Mly2NlQ5PTR4NUi=
LNCaP	NFnRXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXSNVAxNTFyMEDuUS=>	M{TUelI1cA>?		MnzTTWM2OCCxZjCzNFBvVQ>?	NXTBR\|RjOjR6NUS2OVg>
HeLa	NIi5WotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe2N4gz\|ryP	MlvXOFhp		NHTGSmtl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl	NUezZWVxOjR6NE[xN\|U>
HMEC-1	MljUSpVv[3Srb36gRZN{[Xl?	NIj3[pk{ODCwTR?=	M3rJSlI1cA>?		MXnpcoNz\WG\|ZYOg[ZhxemW\|c3nvckBw\sLiVlXHSnI{yqCvUl7B	M3q0WFI1PzFyNkOx
HeLa	MkP0SpVv[3Srb36gRZN{[Xl?	NYPiTllnOW2P	NFrlSZgxNjWq		NVPt[JRW[WKxbHnzbIV{KHSqZTD0c5RidCCKRFHDJIFkfGm4aYT5	M1niblI1PzB5NEe0
ACP02	M2P3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPIS4ozPTBxM{WwM\|UxOG6P	NEfWRnAzPGh?		Ml;L[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>?	NGi1VI0zPDZ4OEW0Oy=>
ACP03	NIPMS5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3jVUFI2OC9\|NUCvOVAxdk1?	MlP4NlRp		MknH[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>?	M{XWOlI1PjZ6NUS3
U87 GBM	M3K5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFy4[3MyODBxM{CwM\|UxOCCwTR?=	MX[3NkBp	M2O5e\|ExOCViZYToZY5wdA>?	MkXSdoVlfWOnczDt[YFvKGOnbHygcpVu[mW{IHL5JFMyNCB3NDygZY5lKDV6wrCl	MWCyOFQ3PDh2MR?=
U87 GBM	MVrGeY5kfGmxbjDBd5NigQ>?	M125SVExOC93MECgUo0>	M{S0NlQ5KGh?	M4XRe\|ExOCViZYToZY5wdA>?	NEnjVWFKdmS3Y3XzJHNmdmW\|Y3XuZ4UuVGmtZTDBcJRmemG2aX;ud{BqdiCQdXPs[YFzKE2xcoDoc4xw\3l?	MlSxNlQ1PjR6NEG=
RPE	NFLKc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX:wMlIwOC52L{CuPE8yKM7:TR?=	NYfPfHlbOjRxNEivO\|IhcA>?	M2TEW2ROW09?	NXf4bW03cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44h[nliY3XscEBkgWOuZTDhdpJme3R?	NFPVPYozPDR3Nk[wNi=>
HT29	M1TYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\jc2hLOThyIH7N	M1TjTlczKGh?		MoLiTWM2OCCxZjCxPFAhdk1?	NYHOU\|VbOjR\|NkiyOlU>
hMSCs	M4\tcmZ2dmO2aX;uJGF{e2G7	M3PSd\|YvOjVibl2=	NH\DenIzPCCq	MlzLSG1UVw>?	NGrCPYV{fGGkaXzpfoV{KEirc4TvcoUhSWOndInsZZRqd25iYX7kJJRp\SCHeIDy[ZN{cW:wIH;mJHBtfXKrcH;0[Y51KEenbnXz	NUPBRWM1OjR\|MUKzOVY>
Huh7	MlHRSpVv[3Srb36gRZN{[Xl?	NYW5U484OC5zL{CuOU8yNjBizszN	M37hclI1cA>?		NIf3dZV{fXCycnXzd4V{KFmWSFTDNkBo\W6nIHX4dJJme3Orb36=	M{XCT\|I1OjZ7Nkey
SKOV3	NFjJVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPW[Xh1OC5yNT2yJO69VQ>?	NUe4SZVLOTBxMkSvOFghcA>?	MnG1SG1UVw>?	MWPt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	NGr1cI8zPDJ{M{iwNS=>
A2780	MkT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4e4RlAvODVvMjFOwG0>	MYCxNE8zPC92ODDo	NGrHOmpFVVOR	MXnt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	NUnldphZOjR{MkO4NFE>
SRA01/04	MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX7YWI9VOC5{IN88US=>	MXK0PEBp	NVnmVm86TE2VTx?=	Ml\Jd5VxeHKnc4Pld{Bk\WyuIIDyc4xq\mW{YYTpc44hfGi{b4XnbEB{fXCycnXzd4lv\yC2aHWgVGk{Uy:Da4SsJJA{QE2DUFugZY5lKEWUS{GvNkB{cWewYXzpcocheGG2aIfhfZM>	NGDkXokzPDF3N{i3PC=>
HLEB3	M2rrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfXNE4zKM7:TR?=	MnLBOFghcA>?	NYDSPIFGTE2VTx?=	NF\oTlJ{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>?	MYOyOFE2Pzh5OB?=
SRA01/04	M176c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLJNE41NzBwODFOwG0>	NUn5ZpVVPDhiaB?=	NGrXdIVFVVOR	NG\leolqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NEXKZXQzPDF3N{i3PC=>
HLEB3	M3X5Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVywMlQwOC56IN88US=>	NHrOeXY1QCCq	NIi5RnZFVVOR	NYj4SHQycW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NHrxe44zPDF3N{i3PC=>
HCT116	NX7lZnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PHflAvOiEQvF2=	MYKxNkBp		M3fIc4VvcGGwY3XzJINmdGxiYYDvdJRwe2m\|IHnu[JVk\WRiYomgdoFlcWG2aX;u	NFfCflIzPDF{MkKzNS=>
CA46	NIn5R2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Hmd\|MwPi9zMj:yOE81QCCwTR?=	NIrNbI41QCCq		MlfUbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCjdDCyOEBidmRiNEigcm3DqA>?	MVSyOFA3PDl3MR?=
PMNs	M{SxdGZ2dmO2aX;uJGF{e2G7	MojJN\|Ahdk1?	MnP5OFghcA>?		NEPvb3JqdmirYnn0d{Bm\m[ncn;jfZRwe2m\|LDDISGFEKGGldHn2bZR6KGGwZDDSZYMh[WO2aY\peJk>	MXmyN\|k5QDZzNx?=
H1299	M{XNV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHrjR2oyyqEQvF5CpC=>	MljINlQwPDhxN{KgbC=>	MVzleIhidm:u	NW\jVVZRcW6lcnXhd4V{KGOnbHyg[IVifGhiYX\0[ZIhOjSq	MWSyN\|kyPjZyOR?=
A549	M1T3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fqdFAvOjVxMD61M\|Eh\|ryP	MmfaNlQwPDhxN{KgbC=>	MWTleIhidm:u	M1nqRolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDDpckBkd26lZX70doF1cW:wIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ?	NX2yWXh1OjN6Nke5PVE>
H1299	M1nseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rBflAvOjVxMD61M\|Eh\|ryP	NFTVOo0zPC92OD:3NkBp	MkDO[ZRp[W6xbB?=	MV3pcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NXXIZ\|Q6OjN6Nke5PVE>
A549	NIjyVlZCeG:ydH;zbZMhSXO\|YYm=	MmjLNE42NzFizszN	NUfoNXdkPDhiaB?=	M3HIfIV1cGGwb3y=	MUfpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MmXxNlM5Pjd7OUG=
H1299	NFrlUZFCeG:ydH;zbZMhSXO\|YYm=	NWfNW5FnOC53L{Gg{txO	MoPXOFghcA>?	MUXleIhidm:u	NFL1WGxqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M2jzc\|I{QDZ5OUmx
SUM149PT	NFjMVYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnf2Nk84NjVxMUCg{txO	NH;FNIw1QCCq	NF\PNWZFVVOR	NWXxe25YcW6mdXPld{Bk\WyuIHTlZZRpKGG2IEKg{txOKGmwc3Xud4l1cX[nbIm=	M{P5VFI{Pzl{NkO4
SUM190PT	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEO3OZY2OC9zMECvNlUxKG6P	MVK0PEBp	MnvYSG1UVw>?	MnTpbY5lfWOnczDj[YxtKGSnYYToJIF1KDVyIH7NJJNmdnOrdHn2[Yx6	NU[xToYyOjN5OUK2N\|g>
HCT1	Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XrNVAvOi9zLkCvOU4xKM7:TR?=	NUmyfnV4OTJxMkSvN\|YwPDhiaB?=		MXXpcoR2[2W\|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=	NEfTUYQzOzd5MECwNC=>
Lovo	Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\1Z4JiOC5{L{GuNE82NjBizszN	NGfaTG4yOi9{ND:zOk81QCCq		M13vSYlv\HWlZYOgZ4VtdCCmZXH0bEBqdiClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	MkjzNlM4PzByMEC=
AGS	NWfyNmhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV[wMlAyPS1zIN88US=>	NVH6V4R1PzJiaB?=		Mn3UbY5lfWOnczDj[YxtKGSnYYToJINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm=	MWeyN\|c1PTB{NB?=
Huh7	MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPFNoUyKM7:TR?=	MlLKNlQhcA>?	NV7Ueo1DTE2VTx?=	M163UpJm\HWlZYOgZYJwfXRiMkClJJZq[WKrbHn0feKh	NW[ybFRtOjN4NEO5N\|M>
ECC1	MYnGeY5kfGmxbjDBd5NigQ>?	NY\wRmwzPTByIH7N	M1H3R\|Uh\A>?	MXrEUXNQ	MnzObY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN?	MUiyN\|U{ODd4OR?=
HEC1A	M2\pcWZ2dmO2aX;uJGF{e2G7	MofUOVAxKG6P	MVm1JIQ>	M1rJeGROW09?	NXjMXVFPcW6mdXPld{BNOUODTdMg[ZhxemW\|c3nvckBkdy22cnXheI1mdnRid3n0bEA2NUG8YVO=	NUj5OoRmOjN3M{C3Olk>
EN1	Mn;QSpVv[3Srb36gRZN{[Xl?	NVvmUGtmPTByIH7N	MkjLOUBl	NFGz[3VFVVOR	MVjpcoR2[2W\|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>?	NFnnSIczOzV\|MEe2PS=>
MFE296	NV7qOYtlTnWwY4Tpc44hSXO\|YYm=	M2PJVlUxOCCwTR?=	NG\EfVY2KGR?	NYXpemltTE2VTx?=	NGfPeG9qdmS3Y3XzJGwyS0GPwrDlfJBz\XO\|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?=	NHvseGozOzV\|MEe2PS=>
HASMCs	NU\I[GRiTnWwY4Tpc44hSXO\|YYm=	M1fNR\|AuPTByIH7N	NEi0clM3KGR?		MWLkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW\|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=>	NFTEO5kzOzVzOES2Oy=>
U373	NXvaRpRTTnWwY4Tpc44hSXO\|YYm=	Ml3FNE4zPS9yLkWvNUDPxE1?	M1nLNFI1KGh?		MXvpcoNz\WG\|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>?	MoPKNlM1PzRzN{G=
ARN8	NWXHRnQyTnWwY4Tpc44hSXO\|YYm=	M3\h[VAvODVvMjFOwG0>	MV6yOEBp		NHOwXodz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>?	NVjJUXpFOjN2N{C1OFA>
MCF7	MkS5SpVv[3Srb36gRZN{[Xl?	M37LTlAvODVvMjFOwG0>	M4\OT\|I1KGh?		NYfRTXJJemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN?	NHvPc2UzOzR5MEW0NC=>
H1299	MVLGeY5kfGmxbjDBd5NigQ>?	MnzyNE4{O+LCk{JCpOK2VQ>?	M{fDclI1NzR6IHi=	MUDEUXNQ	NX;Z[5ZDcW6lcnXhd4V{KEVvY3HkbIVzcW5icILveIVqdiCuZY\lcJMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NXjNb2duOjN2NkG5O\|U>
H1299	NWH0bZlyTnWwY4Tpc44hSXO\|YYm=	MUGwMlUh\|ryP	M1rZNVQ5KGh?	MWnEUXNQ	NWTCSGNrcW6qaXLpeJMhfGinIH3p[5JifG:{eTDwc5RmdnSrYXygZ49u[mmwZTD3bZRpKHOrbHnibY5qdg>?	MWmyN\|Q3OTl5NR?=
H1299	MXXGeY5kfGmxbjDBd5NigQ>?	M4rFbFAvPSEQvF2=	NUi4Omc2PDhiaB?=	MoHHSG1UVw>?	MnzXbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW\|c9MgJINwdWKrbnWge4l1cCC\|aXzpZolvcW5?	NGXNWHQzOzR4MUm3OS=>
MG-63	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVT5O4xEOC5\|IN88US=>	MY[xNk06PiCq	MmPySG1UVw>?	NV;TUpJHcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=>	MlXoNlM1PTF6MUe=
LM8	Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3PEVFAvOyEQvF2=	M3HCd\|EzNTl4IHi=	M{fvOGROW09?	NWHoeXI3cW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=>	M1HmeVI{PDVzOEG3
K562	NGHEe5BHfW6ldHnvckBCe3OjeR?=	NUjLS3NCOC53IN88US=>	NXeycVM3OjRiaB?=	MkTk[ZRp[W6xbB?=	M4PBNoRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv	M2nI[FI{PDNyOUW3
HEL	NUH6S3hoTnWwY4Tpc44hSXO\|YYm=	NU\uZVlqOC53IN88US=>	MUiyOEBp	NGDjOJpmfGijbn;s	M13PfoRm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv	NV\udm1IOjN2M{C5OVc>
HL60	NY\VepJTSXCxcITvd4l{KEG\|c3H5	MVyxJO69VQ>?	NUPKSmQ2OjRiaB?=		M4jGNIlv\HWlZYRCpINmdGxiZHXheIg>	NVTxbJhTOjN2MEC1NVk>
KG1	NWGwUlhGSXCxcITvd4l{KEG\|c3H5	MYexJO69VQ>?	NXXDNmprOjRiaB?=		MWLpcoR2[2W\|wrDj[YxtKGSnYYTo	M1HmNlI{PDByNUG5
Kazumi	Ml;YRZBweHSxc3nzJGF{e2G7	Mlr2NUDPxE1?	NGO3c24zPCCq		NX;FZ5VkcW6mdXPld:Kh[2WubDDk[YF1cA>?	MlzlNlM1ODB3MUm=
K562	M3S0WWFxd3C2b4Ppd{BCe3OjeR?=	MUSxJO69VQ>?	M4\GTFI1KGh?		NU\TV\|Q6cW6mdXPld:Kh[2WubDDk[YF1cA>?	M33tc\|I{PDByNUG5
THP1	M2H6ZmFxd3C2b4Ppd{BCe3OjeR?=	M3;JOlEh\|ryP	MnHaNlQhcA>?		M4fld4lv\HWlZYRCpINmdGxiZHXheIg>	NYHDXWF3OjN2MEC1NVk>
SH-SY5Y	MnvHSpVv[3Srb36gRZN{[Xl?	MkGxNlUxKG6P	MnLGNVYhcA>?		MmTjZ4hidmenczDlfJBz\XO\|aX;uJJBifHSncn6gc4Yh\2WwZYOgbY53d2y4ZXSgbY4h[2ixbHXzeIVzd2xic4nueIhme2m\|LDD1dJRic2ViYX7kJIVn\my3eB?=	NGS0PVYzOzN{NkSyNi=>
HEK293	MUfGeY5kfGmxbjDBd5NigQ>?	MnjNNUDDvU4EoB?=	NUK1Z5RvOThiaNMg		NVjiXIFZcW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC\|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?=	MUKyN\|I5PDh2OB?=
HTK	MYjGeY5kfGmxbjDBd5NigQ>?	MkTlOFAxKG6P	MonZO\|IhcA>?		MlLIbY5pcWKrdIOgWGdHNc7{4pETTY5lfWOnZDDNfY9ncWK{b3LsZZN1KESrZn\ldoVvfGmjdHnvci=>	NWjDc\|c2OjN{OESwNFI>
HTK	MoizSpVv[3Srb36gRZN{[Xl?	M3X4flExOC16MEDuUS=>	NVLPUnAyPzJiaB?=		M2jwb4Jtd2OtczDUS2Yu\|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w	NUK3ZVIzOjN{OESwNFI>
Caco-2	MlzzSpVv[3Srb36gRZN{[Xl?	M3rkZVEhyrWPwrC=	M{fQS\|I1KGh?		MWjk[YNz\WG\|ZYOgV2VTXCCycn;0[YlvKGW6cILld5Nqd25?	MlS3NlMyQTVyN{C=
HeLa	NW\PXWVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWCxNFAhdk1?	M4PyWVI1KGh?	NXXKRo5JTE2VTx?=	MkTPTWM2OCCxZjCxNFBvVQ>?	MWeyN\|E3PTd2OB?=
HeLa	NX7XbVhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;zOFAhdk1?	Mn3DOFghcA>?	NIHQXZlFVVOR	NFPmZmpKSzVyIH;mJFQxdk1?	NILFPGwzOzF4NUe0PC=>
HeLa	M1K3fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLzNlAhdk1?	NFKybm04OiCq	M2XnXGROW09?	NVKxSlZDUUN3MDDv[kAzOG6P	NXXWRXlXOjNzNkW3OFg>
HeLa	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4OwV\|ExNzNyL{WwJI5O	M1fae\|czKGh?	MWHEUXNQ	MoPGbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiTV3QJEjPnM7qbTmgcI9{eyClZXzsd{Bld3OnIHTldIVv\GWwdHz5	NVPyc2lxOjNzNkW3OFg>
MDA-MB-231	M37rOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrENlUuPDByIH7N	MYC0PEBp		MnnXTWM2OCCxZjCyOlMvOm6PwrC=	NIriNIwzOzB3NUG5PC=>
MCF-7	NI\HRlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{D4UlI2NTRyMDDuUS=>	M3rFXVQ5KGh?		MXHJR\|UxKG:oIEKyNE41dk1?	MorHNlMxPTVzOUi=
ECC-1	NYf2RnB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDHNVAxKG6P	NEfm[IgzPCCq	M3\seYV1cGGwb3y=	MlfnbY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn	M{XyTlI{ODJ6OECz
HEC-1A	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYCzTHFbOTByIH7N	M4rRZ\|I1KGh?	NVvFeGdF\XSqYX7vcC=>	NW\vb5d[cW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGGyb4D0c5Rq[yCwdXPs[YkhfG9iM{ml	M2TlXlI{ODJ6OECz
NHAC-kn	M2HJRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnwfZEyOC9zMECvOVAxKG6P	NIflUmsyOiCq	MX7EUXNQ	NHHyeWlKSzVyIH;mJFUxOG6P	NHrweHgzOzBzN{i3NS=>
A549	MkHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXiyOVAhdk1?	NYLVd3poPi15MjDo	NYP0W2loTE2VTx?=	NUmx[XRR[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>?	M13jWFIzQTl2N{iw
MG-63	NY\sXoVbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDNN\|AxKG6P	NX3Ce\|FbOTJiaB?=	M1nzc2ROW09?	MW\pcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gPFYm	MWWyNlc6QTN\|OB?=
MG-63	M4[5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\5WVA2OzByIH7N	NXX5cVY4OjRiaB?=	M2\iTWROW09?	Mn\LbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFY4LQ>?	NIL5eZYzOjd7OUOzPC=>
MG-63	M3XyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnKS4hCOzByIH7N	MX:0PEBp	MUfEUXNQ	M3TFXYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV?	MYCyNlc6QTN\|OB?=
HL60	NYraeWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEW4eGIyPTBvM{WwJI5O	MlT4NlQhcA>?		M1OxeIlv[3KnYYPld{Bk\WyuIHHwc5B1d3Orc9Mge4hmdiClb37j[Y51emG2aX;ud{BpcWeqZYKgeIhidiB{NUCgcm0>	NEfV[\|YzOjd3M{ezPS=>
U937	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nhNlE2OC1\|NUCgcm0>	NH7nelIzPCCq		NHPLV4NqdmO{ZXHz[ZMh[2WubDDhdI9xfG:\|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O	NXrteHBGOjJ5NUO3N\|k>
SCC-6	NGja[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjJNlAxNTN{MECgcm0>	NHHlTHcyOi9{ND:0PEBp	Ml;OSG1UVw>?	NY\jc5R6cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hd2ZiU1PDMVYh[2WubIOgbY4h[SCmb4PlMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy	Mle3NlI2PTJ\|MkG=
U87	M2DWcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3X3XVExOC1\|MECgcoc>	NU\M[5cxOjRiaB?=		MY\pcohq[mm2czD0bIUh[2WubDDndo94fGhidH:gO\|ImKCCjdDCyNFBv\w>?	MX6yNlI4ODh2OR?=
K562	M1HtVmZ2dmO2aX;uJGF{e2G7	M{\sb\|Eh\|ryP	MlHsNVIhcA>?	MX\EUXNQ	NYjjcYpF\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI>	NYrlSVBEOjJzN{mxPVg>
Reh	MoLTSpVv[3Srb36gRZN{[Xl?	M3jaNFAvOy9zIN88US=>	NX7t[YdsOTJiaB?=	MkLFSG1UVw>?	NUGwfYQx\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI>	M3TpdlIzOTd7MUm4

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	EGFR / STAT3 ; PubMed: 31289542 Oncol Lett Expression of EGFR and STAT3 in PC3 cells treated with TSA. PC3 cells were plated in 6-cm dishes, and 0.25, 0.5 or 1 µM TSA was added for 24 h. DMSO was added into the control group wells. Cells were collected and lysed with lysis buffer and the protein expression analyzed via western blotting. Cyclin D1 / CDK6 / CDK4 / p-RB / RB; PubMed: 31289542 Oncol Lett Expression of cyclin D1, CDK6, CDK4 and RB, and the phosphorylation of RB, was detected in PC3 cells treated with TSA for 24 h. MMP-1 / MMP-3 / MMP-13 / TIMP-1; PubMed: 27431944 Mol Med Rep Chondrocytes were pretreated with increasing concentrations of TSA for 2 h, followed by stimulation with 5 ng/ml IL-1β for 24 h. Acetyl-H3 (Lys27) / H3 (96C10) / Acetyl-H4(Lys8) / H4(L64C1); PubMed: 27431944 Mol Med Rep Chondrocytes were treated with increasing concentrations of TSA for 24 h. α-H3Ac / α-H4Ac / α-H3K9Ac / α-H3K9 S10 / α-H3K4 me / α-H3K4 me2 / α-H3K9 me2; PubMed: 23802098 Front Oncol Histone acetylation occurs directly at the promoter region of IL-23R. The ChIP assay demonstrates that TSA treatment results in an increase in the acetylation of histone H3 and H4. A549 cells were cultured in the presence or absence of TSA (250 ng/mL) for a period of 24 h. Subsequently, a ChIP assay was performed using the following antibodies; pan acetyl-histone H3 (H3Ac), pan acetyl-histone H4 (H4Ac), acetyl-histone H3 Lys 9 (H3K9Ac), acetyl-histone H3 Lys 9/14 (H3K9/14ac), acetyl-histone H3 Lys 9 phosphoSer10 (H3K9S10), methyl-histone H3 Lys 4 (H3K4Me), di methyl-histone H3 Lys 4 (H3K4Me2), and di methyl-histone H3 Lys 9 (H3K9Me2). Input DNA serves as a positive control as recommended by the manufacturer (Diagenode). A no antibody control was included to test for non-specific binding (UT, untreated; TSA, Trichostatin A).	31289542 27431944 23802098
Immunofluorescence	α-C/EBPβ / α-HP1α ; PubMed: 21122806 Exp Cell Res 3T3-L1 preadipocytes were grown on coverslips for three days and induced to differentiate by treatment with MDI (48 h) in the presence of vehicle (-TSA) or 87 nM Trichostatin A (+TSA). Under these experimental conditions: A-H Cells were fixed and permeabilized in cold methanol, subjected to IIF with the indicated antibodies, and nuclei were counterstained with DAPI. Scale bar, 5 μm. α-HDAC1 ; PubMed: 29045501 PLoS One MCF-7 cells were treated with indicated concentrations of trichostatin A (optical sections E-H, respectively) for 12 hours, fixed, permeabilized and optical sections were obtained by laser scanning confocal microscopy. Fluorescence signal for HDAC1 is shown in green (left panels), DAPI staining is shown in blue (middle panels), and merged optical sections are shown in the right panels. α-tubulin / acetylated histone 3; PubMed: 27957719 Neurotherapeutics Immunocytochemistry for acetylated α-tubulin (red) and acetylated histone 3 (green) on N2a cells treated with 1 μM TSA, ACY-738, and ACY-775.	21122806 29045501 27957719
Growth inhibition assay	Cell viability (A549 cells); PubMed: 27571418 PLoS One Cytotoxicity of histamine determined by MTT assay in A549 cells. Cell viability (MDA-MB-231 cells); PubMed: 27548148 Int J Mol Sci The human breast cancer cells (MDA-MB-231) were incubated with various concentrations of TSA (0–300 nM) for 24 h. Cell viability was measured by WST-8. Cell viability (PC3 cells); PubMed: 31289542 Oncol Lett PC3 cells were plated in a 96-well plate and treated with different doses of TSA (0, 0.25, 0.5 and 1 µM) for 72 h; an MTT assay was used to measure the effects of TSA on PC3 cell proliferation.	27571418 27548148 31289542

In vivo

Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. ^[1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro HDAC activity: Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×10⁵ cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 10⁶ cpm) of [³H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [³H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [³H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research: ^[1]	- Collapse Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM Incubation Time: 96 hours Method: Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU Dosages: ~5 mg/kg/day Administration: Injection s.c. (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	23 mg/mL (76.05 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Trichostatin A (TSA) SDF

Molecular Weight	302.4
Formula	C₁₇H₂₂N₂O₃
CAS No.	58880-19-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC(C=C(C)C=CC(=O)NO)C(=O)C1=CC=C(C=C1)N(C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04606771	Recruiting	Drug: Osimertinib + Savolitinib\|Drug: Savolitinib + Placebo	Non-Small Cell Lung Cancer	AstraZeneca	September 28 2020	Phase 2
NCT03901053	Recruiting	Device: Reaktiv AFO\|Device: PhatBrace AFO	Foot Injuries and Disorders	Jason Wilken\|Minneapolis Veterans Affairs Medical Center\|Walter Reed National Military Medical Center\|Henry M. Jackson Foundation for the Advancement of Military Medicine\|Center for Veterans Research and Education\|University of Delaware\|Johns Hopkins Bloomberg School of Public Health\|University of Iowa	February 27 2020	Not Applicable
NCT03887650	Recruiting	Drug: Liposomal Bupivicaine 1.3%\|Drug: Bupivacaine 0.5%	Post-operative Pain\|Total Shoulder Arthroplasty\|Osteoarthritis of the Shoulder\|Pain Management	Hartford Hospital	January 14 2019	Phase 4

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?
Answer:
Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

Domatinostat (4SC-202) is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589, NVP-LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA, MK0683) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275, SNDX-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, Depsipeptide, FR 901228, NSC 630176) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Trichostatin A (TSA)